{"id":8059,"date":"2023-04-24T15:18:21","date_gmt":"2023-04-24T13:18:21","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2023\/04\/230424_FR_MaaTPharma-Reponse-FDA_FINAL.pdf"},"modified":"2023-04-24T15:19:15","modified_gmt":"2023-04-24T13:19:15","slug":"230424_fr_maatpharma-reponse-fda_final-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-u-s-fda-lifts-clinical-hold-on-phase-3-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/230424_fr_maatpharma-reponse-fda_final-2\/","title":{"rendered":"230424_FR_MaaTPharma Re\u0301ponse FDA_FINAL"},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-8059","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n